Q-linea AB (publ) (QLINEA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. You have Stuart Gander here, CEO of Qlinia, and I'm joined by Krista Samuelsson, my CFO. Thank you for joining this Q4 report from Qlinia, our year-end report for 2025. Just a quick disclaimer up front on all forward-looking statements. We'll take that as read. So typical format for this presentation is we've had in the past. I'll spend some time here just giving you an update on the commercial progress for the company, some of the context and dynamics we see in the market. Then we'll share a little bit of how our customers are seeing that with their patient impact and some of the evidence that's coming out of usage in the real world, which we're very excited about. And then we'll start to look forward into 2026 before I'll hand over the reins to Krister, who will walk through the financials in our quarterly report. As ever, we'll wrap up the end with some Q&A. So with that, and for those who have very little time and just want the highlights, a few key messages to walk away from on this report. So first of all, 2025 did generate significant growth in the top line. So we're more than 4x greater than previous year. We're excited about that. And consumables revenue obviously also growing and even faster year on year, which is great to see. It's being driven by the installation of the installed base, which I'll get to shortly. We do see, and perhaps most importantly actually, that the commercial pipeline continues to expand and we are seeing it move and develop. I'll talk about that in more detail. And really the exciting thing for us as we look forward is we expect the U.S. to start converting at a faster rate post our FDA clearance for an expanded menu that we're expecting in the first half of 2026. So obviously the pipeline we're tracking on both sid...